Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

December 20, 2017

Study Completion Date

December 20, 2017

Conditions

Atopic Dermatitis

Interventions

DRUG

Omiganan

Omiganan 1%

DRUG

Omiganan

Omiganan 1.75%

DRUG

Omiganan

Omiganan 2.5%

DRUG

Placebo

Vehicle

Trial Locations (1)

LUMC/Centre for Human Drug Research, Leiden

All Listed Sponsors

lead

Maruho Co., Ltd.

INDUSTRY

NCT03091426 - Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter